Tuesday, January 19, 2010

XOMA Reviews Priorities for 2010 and 2009 Accomplishments

January 19, 2010: 07:30 AM ET

BERKELEY, Calif., Jan. 19, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a summary of its priorities for 2010 and accomplishments during 2009.

-snip-

2009 Accomplishments

XOMA 052 and Proprietary Pipeline

-snip-

Biodefense

  • Advanced XOMA 3AB, an anti-botulism antibody, into pre-IND studies.
    Â
  • Obtained $3.9 million in new government contracts for the development of antibodies to the H1N1/H5N1 and SARS viruses.
    Â
  • Presented new XOMA technology for the development and evaluation of multiple antibody “cocktailâ€� formulations.


-snip-
XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 200 employees at its Berkeley, California location. For more information, please visit http://www.xoma.com.

No comments: